Targeted Strategies for Today's Evolving Markets

MissionIR Blog

Category Archives: NRx Pharmaceuticals Inc. NRXP

MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Applies for FDA Commissioner’s Priority Voucher for NRX-100 Ketamine Formulation

NRx Pharmaceuticals (NASDAQ: NRXP) has filed for the newly launched FDA Commissioner’s National Priority Voucher (CNPV) program, seeking accelerated review for NRX-100, its preservative-free intravenous ketamine formulation. The company believes NRX-100 meets all criteria outlined by FDA Commissioner Marty Makary, … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) Forms Investor Relations Partnership With astr Partners

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its subsidiary HOPE Therapeutics announced a strategic investor relations partnership with astr partners, a boutique firm specializing in life sciences. The collaboration comes as NRx advances toward two NDA filings, an … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics to Present at H.C. Wainwright Neuro Perspectives Conference

NRx Pharmaceuticals (NASDAQ: NRXP) and its wholly owned subsidiary HOPE Therapeutics, Inc. announced participation in the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference, set for June 16–17, 2025. Dr. Jonathan Javitt, Founder, Chairman and CEO of NRx and Co-CEO … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Files Abbreviated New Drug Application for Preservative-Free IV Ketamine NRX-100 Amid Ongoing Shortage

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation of ketamine. The submission seeks approval for all existing ketamine indications, including its use in … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Signs Agreement to Acquire Kadima to Launch $100M Psychiatry Clinic Network

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, known for treating suicidal bipolar depression and acute suicidal depression, has signed a definitive agreement to acquire Kadima Neuropsychiatry Institute. The Kadima acquisition agreement (not yet closed) is part of HOPE’s strategy … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Announces $10.3 Million Financing to Expand HOPE Clinic Network, Advances FDA Drug Approval

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, is advancing its twin strategy of expanding a nationwide mental health clinic network while progressing toward FDA approval of its NMDA-based therapies for suicidal depression and bipolar disorder. The company’s wholly owned … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Subsidiary, HOPE Therapeutics, to Expand Interventional Psychiatry Treatment with Kadima Institute Acquisition

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, and its wholly owned subsidiary HOPE Therapeutics, Inc., a medical and technology-driven company, are expanding their footprint in the mental health care sector with the acquisition of Kadima Neuropsychiatry Institute in La … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

MissionIRNewsBreaks – NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) to Present at Wall Street Conference on May 21

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, announced that Founder and CEO Dr. Jonathan Javitt will deliver a company update at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida. NRx is one of six companies … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

NRx Pharmaceuticals Inc. (NASDAQ: NRXP) Is ‘One to Watch’

NRx Pharmaceuticals (NASDAQ: NRXP) is a clinical-stage biopharmaceutical company developing therapies for central nervous system disorders, particularly suicidal depression and PTSD. The company is leveraging its patented NMDA receptor modulation platform with two drugs, NRX-100 (preservative-free ketamine) and NRX-101 (D-cycloserine/lurasidone), that have … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment

Republican Lawmakers Embrace Psychedelic Therapies in Shift Toward Veteran Mental Health Reform 

Rep. Morgan Luttrell (R-Texas), a retired Navy SEAL, is part of a rising wave of Republican lawmakers advocating for the therapeutic use of psychedelics to treat PTSD, depression, and suicidality among veterans—a movement recently spotlighted by The Wall Street Journal. … Continue reading

Posted in NRx Pharmaceuticals Inc. NRXP | Leave a comment